Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.

Objective: Menopause is associated with a range of symptoms, including hot flashes, mood swings, and others that adversely affect the quality of life of women. This study evaluated the effects of a novel nutraceutical combination containing γ-aminobutyric acid (GABA, 50 mg) and EstroG-100 (514 mg) on these symptom clusters using validated questionnaires.

Methods: Eighty women were randomized into active (age: 53.28) or placebo (age: 52.94) groups. During week 1, participants were instructed to take the product whenever they began to experience vasomotor symptoms as pro re nata dosing (PRN dose, "as needed"). For the remainder of the study (weeks 2-5), participants were switched to a daily supplementation phase.

Results: Hot flashes decreased in intensity (P = 0.001, starting day 1) and number (P = 0.002, starting day 2) in the active group compared with placebo. Stress response and anxiety also improved as early as day 1, with PRN dosing (P = 0.042). By day 3, there was significant reduction in stress, mood swings and headaches compared with the placebo group (P = 0.010, P = 0.024, and P = 0.008, respectively). In the daily supplementation phase from week 2 to week 5, improvements in vasomotor symptoms (day 7, P = 0.010), sleep quality (5 wk, P = 0.030), feelings of depression (3 wk, P = 0.028), tension (5 wk, P = 0.004), and sexual function (day 7, P = 0.029) were observed in those randomized to the active group compared with placebo.

Conclusion: The novel nutraceutical combination of Estro-G100 and GABA may help support women during menopause.